@entity2728 Moderates the Relationship Between @entity5 in 541 XXXX Receiving Chemotherapy.

@entity1 @entity308 @entity5 @entity1295 @entity2728
OBJECTIVE: The aim of this study was to examine the effect of @entity2728 on @entity308 via a secondary data analysis of a randomized clinical trial of @entity2728 for @entity1295 in @entity5 @entity1 . The primary aim is to elucidate factors that contributed to the effectiveness of @entity2728 in the parent trial. METHODS: Five hundred forty-one @entity5 @entity1 receiving chemotherapy and experiencing @entity1295 (Brief Fatigue Inventory [BFI] item 3 of >= 3) were randomized to receive 200 mg @entity2728 (n = 260) or placebo (n = 281) daily from baseline (cycle 2) to posttest (cycle 4). @entity1 completed the Center for Epidemiological Studies- @entity308 Scale (CES-D) and Profile of Mood States @entity308 -dejection subscale at baseline and posttest. We used linear regression to address the hypothesis that @entity2728 would be associated with reduced @entity308 , particularly in those experiencing severe @entity1295 (BFI >= 7). RESULTS: @entity2728 did not have a significant effect on @entity308 , even for those @entity1 with severe @entity1295 . However, for subjects with severe @entity1295 (BFI >= 7), those receiving @entity2728 had lower @entity308 scores than did control subjects. @entity2728 significantly moderated the relationship between baseline @entity1295 and CES-D total scores (P = 0.04) and was marginally significant as a moderator for the relationship between baseline @entity1295 and Profile of Mood States @entity308 -dejection subscale scores (P = 0.07). @entity2728 also significantly moderated the relationship between baseline @entity1295 and CES-D positive affect subscale scores (P = 0.003), but not CES-D somatic, negative affect, or interpersonal subscale scores. CONCLUSIONS: @entity2728 differentially impacts @entity308 based on a @entity1 's level of @entity1295 and reduced @entity308 symptoms only in those with extreme @entity1295 . This effect may be driven by increases in positive affective symptoms. These results have significant implications for intervention; in @entity1 with high levels of @entity1295 , @entity2728 might also reduce @entity308 . Future randomized clinical trials are needed to confirm these results.
